- Home
- WILC vs RIGL Comparison
WILC vs RIGL Comparison
Compare WILC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WILC | RIGL |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.6M | 564.7M |
| IPO Year | 2001 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WILC | RIGL |
|---|---|---|
| Price | $29.61 | $38.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 7.9K | ★ 306.5K |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ $13.45 | $85.07 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $17.66 | $24.84 |
| 52 Week High | $37.99 | $52.24 |
Technical Indicators
Market Signals| Indicator | WILC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout WILC G. Willi-Food International Ltd.
G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.